SUBSTANTIAL SHAREHOLDERS

So far as the Directors are aware, immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), the following persons will have an interest or short position in the Shares and/or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the issued Shares of the Company.

		As of the date of this Document (without taking into account the Share Subdivision)		Shareholding upon completion of the [REDACTED] (after taking into account the Share Subdivision)		
Name of Shareholder	**Nature of interest**	**Number and description of Shares**	**Shareholding in total issued capital**	**Number and description of Shares**	**Shareholding in relevant type of Shares**	**Shareholding in total issued capital**
Fosun Pharma Industrial Development[(1)]	Beneficial owner	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
Fosun Pharma[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
Fosun High Tech[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
Fosun International[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
FHL[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
FIHL[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
Mr. Guo Guangchang[(1)]	Interest in controlled corporation	64,790,006 Unlisted Shares	68.47%	[REDACTED]	[REDACTED]%	[REDACTED]%
Mr. Zhao Guanghui (趙光輝)	Beneficial owner	6,364,962 Unlisted Shares	6.73%	[REDACTED]	[REDACTED]%	[REDACTED]%
Mr. Xue Ping (薛平)	Beneficial owner	3,817,076 Unlisted Shares	4.03%	[REDACTED]	[REDACTED]%	[REDACTED]%
Ms. Yang Dongni (楊冬妮)[(2)]	Beneficial owner Interest in controlled corporation	2,897,827 Unlisted Shares	3.06%	[REDACTED]	[REDACTED]%	[REDACTED]%
Mr. Qian Tingzhi (錢庭梔)[(3)]	Interest in controlled corporations	1,854,782 Unlisted Shares	1.96%	[REDACTED]	[REDACTED]%	[REDACTED]%

SUBSTANTIAL SHAREHOLDERS

		As of the date of this Document (without taking into account the Share Subdivision)		Shareholding upon completion of the [REDACTED] (after taking into account the Share Subdivision)		
Name of Shareholder	**Nature of interest**	**Number and description of Shares**	**Shareholding in total issued capital**	**Number and description of Shares**	**Shareholding in relevant type of Shares**	**Shareholding in total issued capital**
China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) (華潤(成都)醫藥產業股權投資基金合夥企業(有限合夥), "**CR Pharma Chengdu Fund**")(4)	Beneficial owner	1,781,320 Unlisted Shares	1.88%	[REDACTED]	[REDACTED]%	[REDACTED]%
China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) (華潤醫藥科技(成都)合夥企業(有限合夥), "**CR Pharma Technology Chengdu**")(4) . . .	Interest in controlled corporation	1,781,320 Unlisted Shares	1.88%	[REDACTED]	[REDACTED]%	[REDACTED]%
Hanwei Huayou Equity Investment Shantou Co., Ltd. (漢威華酉股權投資汕頭有限公司, "**Hanwei Huayou**")(4)	Interest in controlled corporation	1,781,320 Unlisted Shares	1.88%	[REDACTED]	[REDACTED]%	[REDACTED]%
China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Co., Ltd. (華潤醫藥股權投資基金管理(汕頭)有限公司, "**CR Pharma Shantou**")(4)	Interest in controlled corporation	1,781,320 Unlisted Shares	1.88%	[REDACTED]	[REDACTED]%	[REDACTED]%
China Resources Company Limited (中國華潤有限公司)(4)	Interest in controlled corporation	1,781,320 Unlisted Shares	1.88%	[REDACTED]	[REDACTED]%	[REDACTED]%

Notes:

(1) As of the Latest Practicable Date, Mr. Guo Guangchang, directly and indirectly through FHL (which was wholly owned by FIHL, a company controlled by Mr. Guo Guangchang as to 85.29%), was interested in approximately 72.79% of the shares in Fosun International, and (ii) Fosun International, directly and indirectly through its wholly owned subsidiary, Fosun High Tech, was interested in approximately 36.23% of the total share capital of Fosun Pharma. Fosun Pharma Industrial Development was wholly owned by Fosun Pharma. By virtue of the SFO, each of Fosun Pharma, Fosun High Tech, Fosun International, FHL, FIHL and Mr. Guo Guangchang is deemed to be interested in the Shares held by Fosun Pharma Industrial Development.

(2) As of the Latest Practicable Date, Chengdu Jiefurui Investment Co., Ltd. (成都傑弗瑞投資有限公司, "**Chengdu Jiefurui**") was wholly owned by Ms. Yang Dongni. By virtue of the SFO, Ms. Yang Dongni is deemed to be interested in the Shares held by Chengdu Jiefurui. For details of the Shares held by Chengdu Jiefurui, see "History and Development – Capitalization."

(3) As of the Latest Practicable Date, Shanghai Jingxu Changzheng Linghui Investment Center (Limited Partnership) (上海景旭長征淩輝投資中心(有限合夥), "**Jingxu Changzheng**") was held as to approximately 0.93% by Shanghai Jingxu Venture Capital Co., Ltd. (上海景旭創業投資有限公司, "**Jingxu VC**") as its general partner and 9.29% by Shanghai Jingxu Weiyi Venture Capital Management Co., Ltd. (上海景旭巍奕創業投資管理有限公司, "**Jingxu Weiyi**") as a limited partner. Jingxu VC was held as to 50% by Shanghai Zifan Business Consulting Center (Limited Partnership) (上海字凡商務諮詢中心(有限合夥), "**Shanghai Zifan**") and 3% by Mr. Qian Tingzhi. Shanghai Zifan was held as to 1% by Shanghai Kangming Investment Management Co., Ltd. (上海康明投資管理有限公司, "**Shanghai Kangming**") as its general partner and 89% by Mr. Qian Tingzhi as a limited partner. Shanghai Heshi Investment Center (Limited Partnership) (上海禾實投資中心(有限合夥), "**Heshi Investment**") was held as to 1% by Shanghai Kangming as its general partner and 99% by Mr. Qian Tingzhi as a limited partner. Shanghai Jingxu Rongxu Venture Capital Center (Limited Partnership) (上海景旭榕煦創業投資中心(有限合夥), "**Jingxu Rongxu**") was held as to approximately 1.11% by Jingxu Weiyi as its general partner. Each of Shanghai Kangming and Jingxu Weiyi was controlled by Mr. Qian Tingzhi. By virtue of the SFO, Mr. Qian Tingzhi is deemed to be interested in the Shares held by each of Jingxu Changzheng, Heshi Investment and Jingxu Rongxu. For details of the Shares held by each of Jingxu Changzheng, Heshi Investment and Jingxu Rongxu, see "History and Development – Capitalization."

(4) As of the Latest Practicable Date, the general partner of CR Pharma Chengdu Fund was CR Pharma Technology Chengdu. CR Pharma Technology Chengdu was held as to 51% by Hanwei Huayou as a general partner and 6.5% by CR Pharma Shantou as a general partner. The ultimate actual controller of Hanwei Huayou and CR Pharma Shantou was China Resources Company Limited. By virtue of the SFO, each of China Resources Company Limited, CR Pharma Shantou, Hanwei Huayou and CR Pharma Technology Chengdu is deemed to be interested in the Shares held by CR Pharma Chengdu Fund.

Save as disclosed above and in "Statutory and General Information" in Appendix IV to this Document, the Directors are not aware of any person who will, immediately following the [**REDACTED**] (and the [**REDACTED**] of any additional H Shares pursuant to the [**REDACTED**]), have an interest or short position in the Shares or underlying Shares of the Company which would be required to be disclosed to the Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will, directly or indirectly, be interested in 10% or more of the issued voting shares of any other members of the Group.